Clinical Trial: Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)

U.S., April 23 -- ClinicalTrials.gov registry received information related to the study (NCT06937905) titled 'Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)' on April 14.

Brief Summary: Based on the efficacy of tarlatamab in patients with small-cell lung cancer, we aim to assess the efficacy of tarlatamab in patients with Advanced, pulmonary (large-cell only) or gastroenteropancreatic neuroendocrine carcinoma.

Study Start Date: Sept. 01, 2025

Study Type: INTERVENTIONAL

Condition: Neuroendocrine Carcinoma

Intervention: DRUG: Standard of Care Chemotherapy

Study treatment in the arm A is left to the investigato...